3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Preleukemia
1
Myelodysplastic Syndromes
1
Leukemia
1
Hematologic Diseases
1
Cytopenia
1
Bone Marrow Diseases
1
Anemia
1
Interventions
Rituximab
4
Cyclophosphamide
4
Etoposide
3
Dexamethasone
3
ponatinib
2
pomalidomide
2
fludarabine
2
Whole-Body Irradiation
2
Vincristine
2
Sirolimus
2
Prednisone
2
Platelet Transfusion
2
Mycophenolic Acid
2
Lenalidomide
2
Ifosfamide
2
Doxorubicin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
Alemtuzumab
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ricolinostat
1
pembrolizumab
1
nilotinib
1
ibrutinib
1
fludarabine phosphate
1
epratuzumab
1
daratumumab
1
dacetuzumab
1
Tacrolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hematologic Diseases
×
Sertraline
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled